Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 May 2025 | Story Tshepo Tsotetsi | Photo Tshepo Tsotetsi
Multilingualism stakeholder engagement session
Prof Vasu Reddy, UFS Deputy Vice-Chancellor: Research and Internationalisation; guest speaker Prof Leketi Makalela; and Dr Nomalungelo Ngubane, Director of the UFS Academy for Multilingualism.

Multilingualism is not just a concept at the University of the Free State (UFS) – it is a growing practice, a challenge, and an opportunity all at once. This was made clear during a stakeholder engagement session on 7 May 2025, hosted by the Academy for Multilingualism at the UFS’s Bloemfontein Campus, where staff, academics, and strategic partners gathered to reflect on the university’s language journey.

In his reflections, the Deputy Vice-Chancellor for Research and Internationalisation, Prof Vasu Reddy, emphasised that, “Scholarly conversations such as these are not just simply intellectually important, but socially and politically, and it is critical to learn from each other, exchange ideas, and make change.” He described the Academy as a “novel intervention” and noted how engagements like this help “break silos that languages sometimes create” – a crucial step towards realising the promise of multilingualism and translanguaging in academic spaces.

 

Progress, challenges, and collective ownership

In her presentation, Dr Nomalungelo Ngubane, Director of the Academy for Multilingualism, provided an overview of the institutional language policy and its implementation status, now in its third year of a five-year plan. She highlighted key strides: the translation of 116 PhD abstracts into Sesotho, Afrikaans, and isiXhosa; the development of South African Sign Language terminology in psychology; and the training of 16 tutors in translanguaging, among others.

Dr Ngubane stressed the importance of shared ownership of the policy’s rollout. “It’s very important that the language policy is understood by all stakeholders. It’s a collective journey, and it becomes even more powerful when people own it and take it forward into their departments, faculties, and student spaces,” she said. While she acknowledged that meaningful development of African languages as academic mediums is costly and resource-intensive, she noted that small, deliberate steps are being taken.

 

Ubuntu translanguaging: rethinking the classroom

The keynote address was delivered by Prof Leketi Makalela, full professor and founding Director of the Hub for Multilingual Education and Literacies at the University of the Witwatersrand. A globally recognised scholar and the holder of the SARChI Chair in Advancing African Languages for Social Inclusion and Access, Prof Makalela added a powerful perspective rooted in research and teaching practice.

He began his address with a reflection: “I believe I landed on this little rock called Earth to ensure that human beings have deep access to the world in which they were born, and you can only be part of this greater world and make full sense of it through language.”

Later, he challenged the monolingual mindsets that dominate higher education. “People still want to treat languages as different entities, and that’s where the issue is. That’s where the education system is not aligning with the realities of multilinguality.” 

Prof Makalela said multilingual students face dual disadvantages: compromised epistemic access [access to knowledge systems] due to monolingual bias, and diminished identity affirmation. His response? Ubuntu translanguaging – a model that embraces cohabitation of languages and student-led meaning-making.

“It’s a misconception that the lecturer must translanguage,” he said. “It is the student who should translanguage. The lecturer should only facilitate and respect that internal process.”

He outlined a clear, three-step translanguaging teaching method:

• Pre-lesson: Activate prior learning and scaffold vocabulary and concepts.
• During lesson: Create space for multilingual thinking – allow students to write, reflect, and engage in their own languages.

• Post-lesson: Validate understanding, and open the classroom to diverse linguistic expressions.

Prof Makalela stressed that the real innovation lies in normalising these practices institution-wide. “Existing multilingual tutorials are useful, but real transformation happens when every lecturer opens up their lessons to multilingual engagement.”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept